Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Show more

Location: Level 10, Kuala Lumpur, 592000, Malaysia | Website: https://www.cyclacel.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

14.37M

52 Wk Range

$3.08 - $597.60

Previous Close

$9.05

Open

$9.01

Volume

86,073

Day Range

$8.95 - $9.45

Enterprise Value

9.997M

Cash

3.45M

Avg Qtr Burn

-2.689M

Insider Ownership

59.41%

Institutional Own.

6.62%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Oral Fadraciclib (CDK2 & CDK9) Details Solid tumor/s, Lymphoma, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Oral Plogosertib Details Lymphoma, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.